Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based Founder operating in the Therapeutics space. If you think a Founder is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Siro Perez
Co-Founder & CEO of Molecular Warehouse
Follow Siro Perez:
About IP Group, Kira Biotech, Molecular Warehouse: Molecular Warehouse is creating a world where most diseases are prevented, by giving people the power of molecular diagnostics and mHealth.
_______
Nikita Alexandrov
Co-Founder of Molecular Warehouse
Nikita brings advanced expertise in instrumentation and high throughput research techniques. Prior to MW, he founded Permanetix Corporation, developing technology in the field of Fusion energy. Previously, he was the first employee in the aerospace materials testing start-up XEEL Corp, where he developed tools and techniques for high energy testing of space flight hardware for NASA. Nikita graduated from Auburn University (USA) in 2012, with a degree in chemistry, focusing on analytical chemistry, where he received his own lab to conduct chemical plasma reactor research and development. Nikita has an MBA from the University of Alabama (USA).
Follow Nikita Alexandrov:
About Molecular Warehouse: Molecular Warehouse is creating a world where most diseases are prevented, by giving people the power of molecular diagnostics and mHealth.
Peter Hames
Co-Founder & CEO of Big Health
Peter Hames is CEO of Big Health, a digital medicine company he co-founded with clinical psychologist Prof Colin Espie (University of Oxford). Big Health creates automated behavioral medicine programs fuelled by tracked data, and was inspired by Peter’s difficulty in getting access to evidence-based non-drug solutions to his own insomnia. Big Health’s first product, Sleepio, is a digital sleep improvement program featuring personalized Cognitive Behavioral Therapy (CBT) techniques, delivered by virtual animated sleep expert The Prof and his narcoleptic dog Pavlov. In the world’s first placebo-controlled randomised trial for an intervention of its kind, Sleepio was shown to be comparable in effectiveness to face-to-face therapy.
Follow Peter Hames:
About Big Health, Lucky Voice, NHS England, Sleepio: Big Health is a digital therapeutics company operating a healthcare portal to offer behavioral programs for mental health issues.
Colin Espie
Co-Founder & Chief Medical Officer of Big Health
Colin Espie is Founder at Big Health.
Follow Colin Espie:
About Big Health, Sleepio, University of Glasgow, University of Oxford: Big Health is a digital therapeutics company operating a healthcare portal to offer behavioral programs for mental health issues.
Tom Henley
Founder and CEO of Empyrean Therapeutics
Tom Henley is the founder and CEO of Empyrean Therapeutics.
Follow Tom Henley:
About Empyrean Therapeutics: Empyrean Therapeutics develops next generation cell therapies to enable global and affordable cures for diseases.
Amit Nathwani
Founder & Chief Scientific Officer of Freeline
Amit is renowned for his pioneering work on gene therapy for haemophilia B, and was first to show successful correction of bleeding diathesis in patients with severe haemophilia B. Amit is the Director of the Katharine Dormandy Haemophilia Centre at the Royal Free Hospital, and a Senior NIHR Investigator. He is also Professor of Haematology at UCL. He graduated in Medicine from the University of Aberdeen in 1984. In 1997 he moved to St. Jude Children’s Research Hospital, Memphis, USA, to work with Dr Arthur Nienhuis on adeno-associated virus mediated gene transfer. Here he started his pioneering work on gene therapy for haemophilia B. In 2001 he returned to University College London as a Senior Lecturer in Haematology and a Consultant to the National Blood Services in the UK. He was the first to show successful correction of bleeding diathesis in patients with severe haemophilia B, using a distinct gene transfer approach developed in collaboration with Dr’s Davidoff and Nienhuis at St Jude Children’s Research Hospital.
Follow Amit Nathwani:
About Freeline: Freeline Therapeutics is a biotechnology company focused on developing liver directed gene therapies for a range of diseases.
James Field
CEO & Founder of LabGenius
James is founder and CEO of LabGenius. James completed his PhD studies at Imperial College London where his research was focused on re-engineering protein nanocages for biotechnological applications. Prior to his PhD, James completed a BSc in Biology with Microbiology and an MRes in Systems and Synthetic Biology, at Imperial College London. James is an active member of the synthetic biology community having participated in the iGEM competition both as an undergraduate (2009), advisor (2011) and judge (2016). In 2017, James was awarded the BBSRC Innovator of the Year award for early career impact. James is also a fellow of the prestigious Synthetic Biology Leadership Excellence Accelerator Program (LEAP).
Follow James Field:
About LabGenius: LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine.
Susan Greenfield
Founder & CEO of Neuro-Bio
Follow Susan Greenfield:
About Neuro-Bio: Neuro-Bio is a British pharmaceutical company
Baroness Susan Greenfield
CEO & Founder of Neuro-Bio
Susan Greenfield is a neuroscientist, writer, and broadcaster. She has been awarded 30 Honorary Degrees from British and foreign universities and heads a multi-disciplinary research group exploring novel brain mechanisms linked to neurodegenerative diseases such Alzheimer’s and Parkinson’s. She is a Senior Research Fellow at Lincoln College, Oxford and has currently co-founded a biotech company developing a novel approach to neurodegenerative disorders (Neuro-Bio Ltd). In addition, she has published a neuroscientific theory of consciousness,’The Private Life of the Brain’ (2003) and developed a keen interest in the impact of modern technologies on how young people think and feel. This was discussed in her book, ‘ID: The Quest for Identity in the 21st Century’ (2008). In 1998 she received the Michael Faraday Medal from the Royal Society, was awarded a CBE in the Millennium New Year’s Honours List and was granted a non-political Life Peerage in 2001. In 2000 she was elected to an Honorary Fellowship of the Royal College of Physicians and in 2007 to an Honorary Fellowship of the Royal Society of Edinburgh. She was appointed Chancellor of Heriot Watt University in 2005. Further recognition of her work includes L’Ordre National de la Légion d’Honneur from the French Government, and the American Academy of Achievement Golden Plate Award, both received in 2003. Susan was also awarded the Australian Medical Research Society Medal in 2010. In 2011, Susan joined the Advisory Board of the Kusuma School of Biological Sciences at the Indian Institute for Technology, Delhi. In 2012, Susan was offered the Honorary Fellowship of the Institute of Risk Management and also became a Vice Patron of POWER International. Further on in 2012, Susan was selected to serve as the Parliamentary Patron of the Westminster Higher Education Forum, alongside of continuing to be a Parliamentary Patron of the Westminster Education Forum. Continuing through 2012, Susan bacame a Governor of The Florey Institute for Neuroscience and Mental Health and also started to suport the IAB (the International Advisory Board). In January 2014, she was included in the Debrett’s 500, “a recognition of the most influential and inspiring 500 people in Britain.”. Most recently, in July 2014, Susan was awarded as an Honorary Doctorate at Middlesex University.
Follow Baroness Susan Greenfield:
About Neuro-Bio: Neuro-Bio is a British pharmaceutical company
Prof James Davies
Co-Founder of Nucleome Therapeutics
James Davies is the Co-Founder of Nucleome Therapeutics.
Follow Prof James Davies:
About Nucleome Therapeutics: Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat diseases
Prof James Davies
Co-Founder of Nucleome Therapeutics
James Davies is the Co-Founder of Nucleome Therapeutics.
Follow Prof James Davies:
About Nucleome Therapeutics: Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat diseases
Prof Jim Hughes
Co-Founder of Nucleome Therapeutics
Jim Hughes is the Co-Founder of Nucleome Therapeutics and a Professor of Gene Regulation at the University of Oxford.
Follow Prof Jim Hughes:
About Nucleome Therapeutics: Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat diseases
Prof Jim Hughes
Co-Founder of Nucleome Therapeutics
Jim Hughes is the Co-Founder of Nucleome Therapeutics and a Professor of Gene Regulation at the University of Oxford.
Follow Prof Jim Hughes:
About Nucleome Therapeutics: Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat diseases
Dr. Danuta Jeziorska
CEO & Co-Founder of Nucleome Therapeutics
Danuta Jeziorska is the CEO & Co-Founder at Nucleome Therapeutics.
Follow Dr. Danuta Jeziorska:
About Nucleome Therapeutics: Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat diseases
Dr. Danuta Jeziorska
CEO & Co-Founder of Nucleome Therapeutics
Danuta Jeziorska is the CEO & Co-Founder at Nucleome Therapeutics.
Follow Dr. Danuta Jeziorska:
About Nucleome Therapeutics: Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat diseases
Guido Franzoso
Scientific Founder of Kesios Therapeutics
Franzoso joined Imperial College London in June 2007 and is Head of the Centre for Cell Signalling and Inflammation and Professor and Chair of Signal transduction and Inflammation. He was previously at the University of Chicago for 10 years. Franzoso, is the principal founder of Kesios Therapeutics, a spin-out from Imperial College London founded in 2012. Franzoso’s work is highly regarded by the scientific community, as evidenced by numerous high-impact publications in journals, such as, Nature, Science, Cell, Immunity, Nature Cell Biology and Cancer Cell and he has been awarded substantial funding to pursue his research. Recognising the need to translate this research into healthcare benefit, Franzoso was able to raise £3.7M from the MRC for a multi-centre Phase I/IIa trial of DTP3 in multiple myeloma and he has also successfully achieved substantial project funding for both basic and clinical research from the MRC, CRUK and NIH (US). Franzoso owns several patents on intellectual property related to his research. Franzoso holds a medical degree from the University of Padua medical school, Italy and a Ph.D. in microbiological sciences from the Institute of Microbiology at the University of Padua.
Follow Guido Franzoso:
About Imperial College London, Kesios Therapeutics: Kesios Therapeutics, a London, UK-based oncology drug discovery company
Eric Miska
Co-Founder of Storm Therapeutics
Eric is the Herchel Smith Professor of Molecular Genetics and a Senior Group Leader at the Gurdon Institute at the University of Cambridge. He has an appointment as associated faculty at the Cambridge Systems Biology Centre and the Cancer Research UK Cambridge Research Institute. Eric was an EMBO Young Investigator and is a full member of EMBO since 2012. Eric is the 2013 recipient of the Hooke Medal awarded by the British Society of Cell Biology. He joined the faculty of the Wellcome Trust Sanger Institute in Hinxton in 2014 and is a Senior Investigator of the Wellcome Trust. Eric studied mathematics, physics and biology at Heidelberg, Berlin and Mainz and holds a BA in Biochemistry from Trinity College, Dublin. He received his PhD in Pathology from the University of Cambridge, UK, in 2000, working with Professor Tony Kouzarides, and was a postdoctoral fellow in the laboratory of Nobel laureate Bob Horvitz at the Massachusetts Institute of Technology, Cambridge, MA, USA from 2000 to 2004. He started his own research group at the Gurdon Institute in 2005.
Follow Eric Miska:
About Storm Therapeutics, University of Cambridge: Targeting pathways that modify RNA to deliver novel cancer therapeutics
Harry Destecroix
Founder and CEO of Ziylo
Follow Harry Destecroix:
About Ziylo: Ziylo has developed Biomimetic Glucose Binding Molecules (GBM) for Continuous Glucose Monitors (CGM) & Glucose Responsive Insulins (GRI)
George Frodsham
Founder & CEO of MediSieve
George Frodsham founded MediSieve after being awarded his PhD in biochemical engineering from University College London (UCL), during which he developed the magnetic blood filter. As well as being a physicist and engineer, George is an entrepreneur. George was awarded a BBSRC Enterprise Fellowship from the Royal Society of Edinburgh in 2014. Since 1996, only 180 individuals have benefited from this highly competitive and prestigious programme. George has also completed the Entrepreneurship Summer School programme at the London Business School. This equipped him to research target markets and industries and turn his visions into viable businesses.
Follow George Frodsham:
About MediSieve: MediSieve is a therapeutics company developing a platform technology for the treatment of blood-borne diseases.
Himanshu Kataria
Founder, CEO and Managing Director of CLYZ Labs
Himanshu is an experienced NHS Academic Clinician with emergency medicine background (>10 years clinical experience). Himanshu has substantial experience in setup and delivery of clinical research trials, as a specialty lead within Clinical Research Network for the whole of North West Coast of England delivering research in >23 NHS Partner organisations. Himanshu is an MBBS, MBBS, MRCSed (A&E), MRCEM, FRCEM, ALS Instructor. With a number of years in both clinical and research experience, Himanshu has held various consultancy posts in notable hospitals/medical facilities such as Whiston Hospital in Merseyside. He also held the Special Group Lead position within the Clinical Research Network – North West Coast: Research Delivery arm of the NIHR (National Institute of Health Research). In addition to his qualifications as a Medical Doctor, Himanshu has held a number of entrepreneurial roles over the past few years in bio-medical companies such as Indu Stem Cell Technology Plc, and Transgenex Inc in the USA. Dr Kataria is familiar with financial management of the business owing to his experience in Clinical Finance Limited which advised for fundraising for Indu Stem Cell Technology PLC. He continues to serve as a director for Indu Stem Cell Technology PLC.
Follow Himanshu Kataria:
About CLYZ Labs: CLYZ Labs are developing a testing service to select the best drug therapy for personalised cancer treatment.
Sergio Quezada
Founder of Achilles Therapeutics
Sergio Quezada is a Professorial Research Fellow and a Group Leader of the Immune Regulation and Tumour Immunotherapy Laboratory at University College London Cancer Institute. He is an expert in basic and translational research relating to cancer immunology with a focus on T cell immunobiology, immune-regulation, and the interplay between cancerous and immune cells within the tumour microenvironment. He has made seminal contributions to the understanding of the mechanisms underpinning the in vivo activity of checkpoint inhibitors (CPIs), particularly on the mechanisms of action of anti-CTLA-4 antibodies. Sergio has been the recipient of Dartmouth’s John W. Strohbern Medal for excellence in biomedical research, a CRUK Career Development Fellowship and the Cancer Research Institute investigator Award. Most recently he was awarded with a Cancer Research UK Senior Cancer Research Fellowship. Sergio holds a Ph.D. from Dartmouth Medical School. From 2004 to 2010 he held a post-doctoral position in the laboratory of Dr. James Allison at Memorial Sloan-Kettering Cancer Center.
Follow Sergio Quezada:
About Achilles Therapeutics, Achilles Therapeutics, UCL Cancer Institute: Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.
Karl Peggs
Founder of Achilles Therapeutics
Karl Peggs is a Professor of Transplant Science and Cancer Immunotherapy, Scientific Director NIHR Blood and Transplant Research Unit for Stem Cells and Immunotherapies, Scientific Co-Chair and Board Member of the British Society of Blood and Marrow Transplantation, and Honorary Consultant in Haematology/Stem Cell Transplantation at UCLH; he is also an Honorary Consultant (non-clinical) at the Royal Marsden Hospital, London. After taking the position of Senior Lecturer at UCL in 2003 and Head of Adult Stem Cell Transplantation Services, UCLH, he spent over 2 years at MSKCC, NYC, USA in the laboratory of Professor James Allison studying murine models of regulatory checkpoint blockade. He runs a joint Research Laboratory with Dr Sergio Quezada in the UCL Cancer Institute and his research interests include viral infections, immune reconstitution, adoptive cellular therapies, and regulatory checkpoint-directed immune-therapeutics. More recently he has established the clinical translational side of the academic CAR T cell programme at UCLH. Karl was trained at the John Radcliffe Hospital, Oxford, Addenbrooke’s Hospital, Cambridge, and UCH, London.
Follow Karl Peggs:
About Achilles Therapeutics: Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.
Chris Spencer
Co-Founder and Head of Innovation of Genomics
Chris Spencer is Founder of Genomics PLC and serves as its Director. Chris Spencer’s collect, curate, analyse and interpret very large amounts of genetic data to help understand human diseases. His career has happily coincided with an era of collaboration it made major inroads into understanding of human genetics. He has played a lead analytical role in the International HapMap project and the Wellcome Trust Cases Controls Consortium. As a young scientist, his early work in large scale human data was awarded the Corcoran Memorial Prize from the Department of Statistics at the University of Oxford, which is awarded every two years for outstanding graduate work. His works are Cell-Mediated Immune Mechanisms, Visceral Leishmaniasis and Large Vessel Ischemic Stroke.
Follow Chris Spencer:
About Genomics: Genomics plc aiming to lead the genomic transformation of healthcare.
Gil McVean
Co Founder & Director of Genomics
Gil McVean is Professor of Statistical Genetics at the University of Oxford and Head of Bioinformatics and Statistical Genetics at the Wellcome Trust Centre for Human Genetics. After an undergraduate training in Zoology, he obtained a PhD with Laurence Hurst in Cambridge and worked with Brian and Deborah Charlesworth in Edinburgh before joining Oxford in 2000. His research focuses on understanding the molecular and evolutionary processes that shape genetic variation in populations and the relationship between genetic variation and phenotype. He has made contributions to our understanding of areas including recombination hotspots, historical patterns of natural selection, the male mutation rate, human genetic variation, the role of HLA in complex disease and genealogical processes. He has played a leading role in the HapMap and 1000 Genomes Projects and currently works on organisms from HIV to malaria.
Follow Gil McVean:
About Genomics: Genomics plc aiming to lead the genomic transformation of healthcare.
Nigel Dimmock
Founder of VirionHealth
Follow Nigel Dimmock:
About University of Warwick, VirionHealth: VirionHealth is a biotechnology company
Andrew Easton
Founder of VirionHealth
Follow Andrew Easton:
About University of Warwick, VirionHealth: VirionHealth is a biotechnology company
Brendan McNutt
Founder and Chairman of Bryn Melyn Care
Follow Brendan McNutt:
About Bryn Melyn Care: Bryn Melyn Care is a leading provider of therapeutic residential care, independent education, and integrated clinical services.
Anna Perdrix Rosell
Co-Founder & Co-CEO of Sixfold Bioscience
Anna Perdrix Rosell is the Co-Founder & Co-CEO at Sixfold Bioscience.
Follow Anna Perdrix Rosell:
About Sixfold Bioscience: Sixfold Bioscience develops and researches on biotechnology advances for RNA therapies.
George Foot
Co-Founder & Co-CEO of Sixfold Bioscience
George Foot is the Co-Founder & Co-CEO at Sixfold Bioscience.
Follow George Foot:
About Sixfold Bioscience: Sixfold Bioscience develops and researches on biotechnology advances for RNA therapies.
Michael McArthur
CSO and Co-Founder of Procarta Biosystems
Michael McArthur(CSO, Co-Founder) is the Professor of Nanomedicine at the Norwich School of Medicine, UEA. He is a Molecular Microbiologist with over 20 years experience of academic and biotechnology research. His defining scientific interest is how the control of bacterial genes can be used to create new antibacterials. He leads multidisciplinary research teams with expertise in: molecular biology, microbiology, chemistry, biophysical characterisation and formulation. Michael gained his PhD from University of Cambridge and has held academic positions in the EU (John Innes Centre, ICMB in Crete) and University of Washington, Seattle. Whilst there his technologies were used to found a diagnostics company, Regulome Inc, for whom he served as Director of Research. He is named on 15 patents and help raise $30m in private and grant funding.
Follow Michael McArthur:
About Procarta Biosystems: Procarta Biosystems develops antibacterials through an adaptable DNA-based platform to counter the rise of drug-resistant bacterial strains.
Sarah Gilbert
Co-Founder & Professor of Vaccinology of Vaccitech
Professor Sarah Gilbert is Professor of Vaccinology at Oxford University and the programme director for a Wellcome Trust Strategic Award on Human and Veterinary vaccines at the Jenner Institute. She is a member of the Oxford University Clinical Biomanufacturing Facility management committee, and an acknowledged expert in the preclinical and clinical development of viral vectored vaccines.Professor Gilbert’s chief research interest is the development of vaccines that work by inducing strong and protective T cell responses, in addition to working on the development of the viral vector platform technology and its application in rapid vaccine development for emerging pathogens.
Follow Sarah Gilbert:
About Vaccitech: Vaccitech is creating novel vaccines that elicit strong responses from helper and cytotoxic T-cells.
Marcelo Bravo
Co Founder & Chief Executive Officer of OxVax
Marcelo Bravo is the Executive Chairman & Founder of Oxford Phamascience Group & he attended University of Oxford in 2017.
Follow Marcelo Bravo:
About Oxford Phamascience Group, OxVax: OxVax focused on the development of an advanced next-generation dendritic cell vaccine platform for the treatment of solid tumor cancers.
Sophia Karagiannis
Scientific Founder of Epsilogen
Sophia is a Reader in translational cancer immunology at KCL and a globally-recognised expert on the use of IgE antibodies to fight cancer. She co-founded and Chairs the Task Force on AllergoOncology and her group collaborates closely with the CRUK Centre for Drug Development. She holds a PhD from King’s College London.
Follow Sophia Karagiannis:
About Epsilogen: Epsilogen is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.
Neal L Millar
Co Founder & CMO of Causeway Therapeutics
Neal is an Academic Consultant Orthopaedic Surgeon specialising in shoulder surgery having completed fellowships in Sydney and New York and is an expert in human tendinopathy.
Follow Neal L Millar:
About Causeway Therapeutics, University of Glasgow, University of Glasgow: A bio pharmaceutical spin out emerging.
Derek Gilchrist
Co Founder & CEO of Causeway Therapeutics
Derek is a principal investigator at the University of Glasgow and leads the scientific and technical development of TenoMiR™.
Follow Derek Gilchrist:
About Causeway Therapeutics, University of Glasgow, University of Glasgow: A bio pharmaceutical spin out emerging.
Stuart Cockerill
Founder and Chief Scientific Officer of ReViral
Stuart Cockerill PhD Chief Scientific Officer, Founder Stuart was the Principal Investigator on a Wellcome Trust funded Project, on behalf of ReViral. He obtained his PhD in Organic Chemistry at the University of Leeds. After a Postdoctoral fellowship at Cornell University, he joined the GSK heritage company, the Wellcome Foundation and over the next 15 years led drug discovery projects in Pesticides, Immunology, Virology and Oncology. His key achievement was leading the erbB2 Oncology Project Team that discovered Tykerb™ for which Stuart is a named inventor. In December 2000, Stuart joined Arrow Therapeutics as Head of Chemistry and subsequently as Research Director. Stuart remained as Head of Arrow until the end of 2010. Stuart held the position of Senior Lecturer in Medicinal Chemistry at the University of Durham. His key achievements were two clinical Proof of Concept drug candidates involving novel approaches to the treatment of Respiratory Syncytial Virus and Hepatitis C Virus infection. Stuart is an author of over 70 papers, patents and book chapters.
Follow Stuart Cockerill:
About ReViral: ReViral is a biotechnology company that develops and offers antiviral therapies for patients.
Malcolm Weir
Founder & CEO of Heptares Therapeutics
Former Visiting Professor of Biochemistry at Imperial College, London. Former Head of the Molecular Sciences Division of Glaxo Wellcome Inc. (present Glaxo Smithkline plc.) Former CEO of Inpharmatica Ltd.（present Galapagos NV). Founder and CEO of Heptares Therapeutics Ltd.
Follow Malcolm Weir:
About Heptares Therapeutics, Sosei Group: Heptares Therapeutics develops novel, small-molecule drugs for G-protein-coupled receptors (GPCRs).
Herbert Oakes
Founder & CEO of NOXSUDOR THERAPEUTICS LIMITED
Herbert Oakes, non-executive director, is an investment banker and builder of high technology life sciences companies. He is currently a Managing Director of Oakes, Lyman & Co. Limited an investment banking firm specialising in high-tech healthcare; a Managing director of Hycroft Advisors, a global investment banking firm specialising in arranging capital for private equity partnerships; and CEO of NoxSudor Therapeutics Limited, a start-up medical business developing a therapy for hot flashes and night sweats for menopausal women. He is an advisor of Wilton Corporate Finance Limited.
Follow Herbert Oakes:
About NOXSUDOR THERAPEUTICS LIMITED: First prescription medical device to control sweating
Allison Jeynes-Ellis
Co-Founder & CEO of Avillion
Over 20 years of senior leadership experience in the pharmaceutical industry. Significant global drug development experience and successful EU and US drug approvals across a range of therapeutic areas. Leadership of global clinical development teams for Phase 3, including CRO selection and management. Strong networks within the pharma industry and relevant regulatory bodies
Follow Allison Jeynes-Ellis:
About Avillion: Avillion LLP, a London, UK-based company that focuses on clinical co-development of therapeutics.
Michael Leek
Chief Executive & Founder of TC BioPharm
Michael Leek is the Chief Executive and founder at TC BioPharm.
Follow Michael Leek:
About TC BioPharm, University of Aberdeen: TC BioPharm developing safer, cheaper, consistent and durable CAR-T drugs for hematological and solid tumors.
Angela Scott
Chief Operating Officer & Founder of TC BioPharm
Angela Scott is the Founder and Chief Operating Officer at TC BioPharm.
Follow Angela Scott:
About MIT Global Entrepreneurship Bootcamp, TC BioPharm: TC BioPharm developing safer, cheaper, consistent and durable CAR-T drugs for hematological and solid tumors.
Richard Mcconnell
Co-Founder & COO of Liopa
Follow Richard Mcconnell:
About Anaeko, Liopa: Liopa’s LipRead deciphers speech from lip movements. It uses AI and deep learning for automated lip reading.
Vincenzo Cerundolo
Founder of iOx Therapeutics Ltd.
Professor Cerundolo is Professor of Immunology at the University of Oxford and Director of the MRC Human Immunology Unit at the Weatherall Institute of Molecular Medicine. He was the first to show the mechanism of ligand binding of lipids to CD1d molecules and their subsequent presentation to lymphocytes. In addition, He was able to demonstrate the importance of iNKT cells in enhancing antigen specific T and B cell responses and their ability to abolish the immuno-suppressive activity of myeloid derived suppressor cells. This work led to the development of the engineered iNKT agonists being developed by iOx as potential immunotherapy candidates. He discovered the technology that is the basis for iOx Therapeutics and acts as scientific advisor to iOx.
Follow Vincenzo Cerundolo:
About iOx Therapeutics Ltd.: iOx Therapeutics Ltd. operates as an immuno-oncology company.
Benedikt Reinke
Co-Founder & Managing Director of Sympatient
Benedikt Reinke is the Co-Founder & Managing Director at Sympatient GmbH
Follow Benedikt Reinke:
About Sympatient: Sympatient is building the first digital anxiety clinic.
Scott Crowe
Founder and CSO of VHSquared
Follow Scott Crowe:
About VHSquared: VHsquared is dedicated to the development of novel antibody domains engineered to be stable in the GI tract.
Gordon Dougan
Founder of VHSquared
Follow Gordon Dougan:
About VHSquared: VHsquared is dedicated to the development of novel antibody domains engineered to be stable in the GI tract.
Jan Robinson
Founder of VHSquared
Follow Jan Robinson:
About VHSquared: VHsquared is dedicated to the development of novel antibody domains engineered to be stable in the GI tract.
Rod Richards
Founder, CEO of VHSquared
Follow Rod Richards:
About VHSquared: VHsquared is dedicated to the development of novel antibody domains engineered to be stable in the GI tract.
Deborah O’Neil
Founder & CEO of NovaBiotics
Follow Deborah O’Neil:
About BEAM Alliance, NovaBiotics: NovaBiotics Ltd is a clinical-stage biotechnology company.
David Jones
CSA, Co-Founder, Director of Re-Vana Therapeutics
David Jones is the Elected Fellow at Royal Statistical Society.
Follow David Jones:
About Irish Academy of Engineering, Queen’s University Belfast, Re-Vana Therapeutics, Royal Academy of Engineering, Royal Statistical Society, The Institute of Materials, Minerals and Mining, The Royal Society of Chemistry: Re-Vana Therapeutics is a ocular pharmaceuticals & drug delivery company.
Raghu Raj Singh Thakur
Founder & CTO of Re-Vana Therapeutics
Raghu Raj Singh Thakur is the Founder & CTO at Re-Vana Therapeutics.
Follow Raghu Raj Singh Thakur:
About Re-Vana Therapeutics: Re-Vana Therapeutics is a ocular pharmaceuticals & drug delivery company.
Pamela Shaw
Founder of Keapstone Therapeutics
Pamela Shaw is the Vice President and Head of the Faculty of Medicine and Dentistry, University of Sheffield and Director of the Sheffield Institute for Translational Neuroscience (SITraN). She is also Director of the NIHR Biomedical Research Centre Translational Neuroscience for Chronic Neurological Disorders. Professor Shaw is a clinician scientist and world leading expert on mechanisms and treatment of motor neuron disease. She has published over 425 papers and has an H Index of 88.
Follow Pamela Shaw:
About Keapstone Therapeutics: Keapstone Therapeutics is the next generation of drugs targeting a key pathway in neurodegeneration.
Jen Hyatt
Founder and Chief Executive of Big White Wall
Widely recognised for achievements in the fields of social entrepreneurship and digital technology. Has founded or co-created over 30 organizations worldwide, ranging from the National Telephone Helplines Association in the UK to a major grant-making foundation in the Balkans. 2007, founded Big White Wall, recognizing stigma and poor access were preventing millions from getting mental health support; guides strategic growth while launching new enterprises focused on using technology to improve access to legal advice and a digital approach to the improved social, physical and psychological health of teenagers. 2013, created the Collaborative on Health and Technology (ChaT) to help evidence-based digital healthcare companies achieve scale in the UK. Public speaker. Named: one of top 50 innovators in healthcare, Health Service Journal; Schwab Foundation Global Social Entrepreneur (2015); WCIT Social Entrepreneur of the Year (2015); Red Magazine’s Digital Woman of the Year (2015). Recipient, NatWest Everywoman Iris Award (2015). In 2015, Jen was invited to be a Fellow of the Royal Society of Arts as well as sit on the Strategy Committee of the Guy’s and St Thomas Charity.
Follow Jen Hyatt:
About Big White Wall: Big White Wall is a digital mental health and well-being service supporting members through contracts in healthcare and other markets.
Davidson Ateh
Co-Founder & CEO of BioMoti
Davidson is an entrepreneur operating in the life sciences. He has an interdisciplinary scientific background in bioengineering and was a past recipient of the prestigious Royal Society of Edinburgh/BBSRC Enterprise Fellowship. Davidson has significant technology translation experience including proof-of-concept studies, IP protection, non-dilutive grant applications, partnering, licensing and raising investment. He has won awards for his scientific and commercial activities. Davidson is a co-inventor of the Oncojan™ drug delivery platform, co-founder of BioMoti and leads product and business development activities.
Follow Davidson Ateh:
About BioMoti: BioMoti seeks to transform the treatment of cancer by targeted delivery of therapeutics to the intracellular space of cancer cells
Charles Large
Founder and CEO of Autifony Therapeutics
Charles Large received his first degree and PhD from the University of Bristol and has more than 20 years of experience of drug discovery and development in the pharmaceutical industry. Before founding Autifony, he was Director of Molecular and Cellular Biology within the Neuroscience Centre of Excellence for Drug Discovery at GlaxoSmithKline, and has worked on programs focused on schizophrenia, Alzheimer’s disease, epilepsy, bipolar disorder, and major depression. He is an expert on drugs that modulate voltage gated ion channels and their application to neurological and psychiatric disorders. He has built up a reputation in the field of sodium channel blocking drugs, and has collaborated widely with academic groups. He has authored over 50 papers, book chapters and patents relating to ion channel modulators.
Follow Charles Large:
About Autifony Therapeutics: Autifony Therapeutics is a biotechnology company developing medicines to treat hearing disorders such as hearing loss and tinnitus.
Billy Boyle
CEO and Co-Founder of Owlstone Nanotech
Since co-founding Owlstone, Billy has been overseeing the development and implementation of the detection technology with nanotechnology foundry partners. He is also active in business development, demonstrating to partners how the Owlstone technology can used to realise a paradigm shift in detection applications and deployment scenarios. Billy is heavily involved in the creation and realisation of new technologies and IP. Prior to joining Owlstone Billy was a Research Associate in the Microsystems and Nanotech group at Cambridge University. In an academic / industry consortium he designed and developed silicon-opto hybrid devices for next generation telecoms systems.
Follow Billy Boyle:
About Owlstone Nanotech: OWLSTONE is a platform technology, where regardless of the application, hardware remains the same & the app is enabled through software.
Douglas Higgins
Founder & Director of Mujo Mechanics
Douglas Higgins is the Founder & Director at Mujo Mechanics.
Follow Douglas Higgins:
About Mujo Mechanics: Mujo Mechanics provides smart devices and intelligent cloud platform for a data-driven approach to musculoskeletal health.
Adrian Hayday
Co-Founder of GammaDelta Therapeutics
Adrian Hayday was trained in biochemistry at Cambridge, and obtained a PhD in molecular virology from London University. He began studying immunology in 1982 at MIT, where he and his colleagues first described the wholly unanticipated T cell receptor gamma chain genes. Since then Professor Hayday has used many parameters to establish that gamma-delta T cells are clearly distinct from conventional T cells. Those parameters include the cells’ responses to different products of a novel gene family expressed at body surfaces, that Professor Hayday and his colleagues identified. He showed that this unique biology allows gamma-delta T cells to make rapid responses to tissue dysreguation, rather than to specific pathogens, and thereby to monitor tissue integrity. This may explain Professor Hayday’s observation that gamma-delta T cell deficiency is associated with a profound susceptibility to skin carcinogens, findings which were instrumental in promoting his and others’ interest in the cells’ clinical application. In other clinical activities, he directed a team describing the human immune response to vaccination and described the unique properties of human autoantibodies. Additionally, he is the lead-investigator of a Wellcome Trust-supported, multi-centre, high-throughput phenotyping screen identifying novel genetic regulators of the immune system. Professor Hayday has authored over 200 papers, of which he is first, last, or corresponding author on over 120, and of which 150 are original research contributions. He has received many awards, including the William Clyde deVaneMedal, Yale College’s highest honour for scholarship and teaching, an honorary fellowship of King’s College London, and the King’s College Business Award, 2008. He was elected to lead the British Society of Immunology (2005-09) and has organized many scientific meetings including the 2014 Gordon Conference in Immunochemistry and Immunobiology, and the scientific programme for the 2012 European Congress of Immunology. He is an elected fellow of the Academy of Medical Sciences and of the Royal Society. He has formally advised many institutions including Institut Pasteur; the Max Planck Institute; Kyoto University, the Wellcome Trust, and Cancer Research UK, whose science committee he chaired for three years. He has participated in many aspects of the biotech/pharmaceutical sector, including membership of the MedImmune SAB, and was a co-founder of ImmunoQure AG before co-founding GammaDelta Therapeutics in 2016.
Follow Adrian Hayday:
About GammaDelta Therapeutics: GammaDelta Therapeutics is developing the potential of gamma delta (γδ) cells
Robin Marriott
Co-Founder and Executive Vice President of Pharmaceutical Development of PowderMed
PowderMed at Co-Founder.
Follow Robin Marriott:
About PowderMed: PowderMed developed the Particle Mediated Epidermal Delivery (PMED) technology.
Hakim Yadi
CEO & Co-Founder of Closed Loop Medicine
Hakim Yadi is the CEO and Co-Founder at Closed Loop Medicine.
Follow Hakim Yadi:
About : Developing personalised digital healthcare solutions to improve outcomes for patients and clinicians
Sheraz Daya
Founder, Chairman & Medical Director of Centre for Sight
Follow Sheraz Daya:
About Centre for Sight: Centre for Sight provides eye care services, from basic diagnostic and therapeutic services to complex operative procedures.
Martin Schoel
Founder of ChooseHelp
Follow Martin Schoel:
About ChooseHelp: ChooseHelp provides private addiction treatment through a network of treatment centers and drug rehabilitation centers.
Isabel Van De Keere
Founder and CEO of Immersive Rehab
Isabel is an experienced innovation strategist & manager, researcher, product designer, experimentalist, and collaborator across disciplines. She is passionate about science, healthcare technologies, digital health, immersive technologies (VR/AR) and its applications in healthcare, using tech for good, social entrepreneurship, and promoting women in tech.
Follow Isabel Van De Keere:
About Immersive Rehab: IR creates interactive physiotherapy programmes in Virtual Reality that improve the effectiveness of physical & neuro-rehabilitation.
Janet Eyre
Co-Founder of Limbs Alive
Janet Eyre is Co-Founder at Limbs Alive.
Follow Janet Eyre:
About Limbs Alive: Established in 2010, Limbs Alive specialises in the rehabilitation of the hand and arm for people of all ages who have hemiplegia, often
Janice Pearse
Co-Founder of Limbs Alive
Janice Pearse is Co-Founder at Limbs Alive.
Follow Janice Pearse:
About Limbs Alive: Established in 2010, Limbs Alive specialises in the rehabilitation of the hand and arm for people of all ages who have hemiplegia, often
